KSB represents Glenmark Pharmaceuticals in acquisition of Medicamenta
Glenmark Pharmaceuticals Ltd. is the Indian leader in the development of newmolecules in mainly inflammation and metabolic disorders. The company operatesin more than eighty countries worldwide and the acquisition of Medicamenta a.s.represents a strategic entry into two of the fastest growing markets in the EU.
Other articles
KŠB Confirms Its Position in the Chambers Global Guide 2026
In the latest edition of the prestigious Chambers Global Guide 2026, KŠB once again reaffirms its strong position among the leading law firms on the Czech market. Recognition across all four ranked practice areas confirms the stability of our teams and the long-term trust of our clients.
KŠB na společném fóru soudců a advokátů
Dne 12. února 2026 se v Brně uskutečnil 2. ročník společného setkání zástupců ze soudnictví a advokacie pod záštitou České advokátní komory a Nejvyššího správního soudu. Naši advokátní kancelář na tomto významném fóru zastupovali Petra Mirovská a Jakub Mehl.
KŠB Advises J&T Banka, UniCredit and PPF banka on the Next Phase of EMMA Capital’s Bond Programme
KŠB has continued its legal advisory role in connection with investment group EMMA Capital’s bond programme, which has been generating sustained and strong investor interest.
